Sphingomyelinase activity promotes atrophy and attenuates force in human muscle fibres and is elevated in heart failure patients.
Ca2+ sensitivity RNAseq
Heart failure
Skeletal muscle
Sphingomyelinas
Journal
Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
26
01
2022
received:
13
09
2021
accepted:
30
05
2022
pubmed:
20
7
2022
medline:
6
10
2022
entrez:
19
7
2022
Statut:
ppublish
Résumé
Activation of sphingomyelinase (SMase) as a result of a general inflammatory response has been implicated as a mechanism underlying disease-related loss of skeletal muscle mass and function in several clinical conditions including heart failure. Here, for the first time, we characterize the effects of SMase activity on human muscle fibre contractile function and assess skeletal muscle SMase activity in heart failure patients. The effects of SMase on force production and intracellular Ca Sphingomyelinase reduced muscle fibre force production (-30%, P < 0.05) by impairing sarcoplasmic reticulum (SR) Ca The present findings implicate activation of skeletal muscle SMase as a mechanism underlying human heart failure-related loss of muscle mass and function. Moreover, our findings strengthen the idea that SMase activation may underpin disease-related loss of muscle mass and function in other clinical conditions, acting as a common patophysiological mechanism for the myopathy often reported in diseases associated with a systemic inflammatory response.
Sections du résumé
BACKGROUND
Activation of sphingomyelinase (SMase) as a result of a general inflammatory response has been implicated as a mechanism underlying disease-related loss of skeletal muscle mass and function in several clinical conditions including heart failure. Here, for the first time, we characterize the effects of SMase activity on human muscle fibre contractile function and assess skeletal muscle SMase activity in heart failure patients.
METHODS
The effects of SMase on force production and intracellular Ca
RESULTS
Sphingomyelinase reduced muscle fibre force production (-30%, P < 0.05) by impairing sarcoplasmic reticulum (SR) Ca
CONCLUSIONS
The present findings implicate activation of skeletal muscle SMase as a mechanism underlying human heart failure-related loss of muscle mass and function. Moreover, our findings strengthen the idea that SMase activation may underpin disease-related loss of muscle mass and function in other clinical conditions, acting as a common patophysiological mechanism for the myopathy often reported in diseases associated with a systemic inflammatory response.
Identifiants
pubmed: 35852046
doi: 10.1002/jcsm.13029
pmc: PMC9530516
doi:
Substances chimiques
Ribosomal Proteins
0
Sphingomyelin Phosphodiesterase
EC 3.1.4.12
Proteasome Endopeptidase Complex
EC 3.4.25.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2551-2561Subventions
Organisme : Swedish Heart Lung Foundation
Organisme : Swedish Research Council
ID : 2015-02338
Organisme : Swedish Research Council
ID : 2019-01629
Organisme : Swedish Research Council
ID : 2018-02576
Organisme : Swedish Research Council for Sports Science
ID : P2019-0060
Organisme : Swedish Research Council for Sports Science
ID : FO2018-0019
Organisme : Swedish Research Council for Sports Science
ID : FO2017-0018
Organisme : Swedish Research Council for Sports Science
ID : D2016-0036
Informations de copyright
© 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
Références
J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):2259-2261
pubmed: 34904399
Skelet Muscle. 2012 Jan 18;2(1):2
pubmed: 22257771
Circ Res. 1993 Aug;73(2):405-12
pubmed: 8330383
Am J Physiol Cell Physiol. 2010 Sep;299(3):C549-51
pubmed: 20573998
J Biol Chem. 1985 Mar 25;260(6):3440-50
pubmed: 3838314
Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8681-6
pubmed: 10890909
Ann Rheum Dis. 2015 Oct;74(10):1907-14
pubmed: 24854355
Am J Physiol Cell Physiol. 2010 Sep;299(3):C552-60
pubmed: 20519448
Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1112-7
pubmed: 20080539
J Physiol. 1987 Sep;390:285-93
pubmed: 3443937
J Appl Physiol (1985). 2012 May;112(9):1538-45
pubmed: 22362402
J Lipid Res. 2002 May;43(5):815-23
pubmed: 11971953
Physiol Rev. 2015 Jul;95(3):1025-109
pubmed: 26133937
Am J Physiol Lung Cell Mol Physiol. 2019 Apr 1;316(4):L679-L690
pubmed: 30702345
Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14440-5
pubmed: 11717410
Cell Microbiol. 2019 Nov;21(11):e13065
pubmed: 31155842
J Cell Biol. 2003 Mar 17;160(6):919-28
pubmed: 12629052
Nat Protoc. 2017 Sep;12(9):1763-1776
pubmed: 28771237
Eur Heart J. 2003 Dec;24(24):2221-6
pubmed: 14659774
FASEB J. 2004 Jan;18(1):39-51
pubmed: 14718385
Dis Model Mech. 2013 Jan;6(1):25-39
pubmed: 23268536
J Biol Chem. 1998 Feb 13;273(7):4081-8
pubmed: 9461601
Eur J Heart Fail. 2014 May;16(5):519-25
pubmed: 24596158
Circulation. 2000 Dec 19;102(25):3060-7
pubmed: 11120695
Cytokine Growth Factor Rev. 2021 Feb;57:93-111
pubmed: 32475760
Skelet Muscle. 2015 Aug 20;5:26
pubmed: 26301072
Biochem Biophys Res Commun. 1998 Nov 18;252(2):524-8
pubmed: 9826564
J Cell Sci. 2007 Feb 1;120(Pt 3):407-16
pubmed: 17213336
Am J Physiol Lung Cell Mol Physiol. 2015 Sep 15;309(6):L614-24
pubmed: 26138644
Front Physiol. 2015 Jan 21;5:530
pubmed: 25653619
FASEB J. 2005 Mar;19(3):461-3
pubmed: 15611152
J Cachexia Sarcopenia Muscle. 2022 Oct;13(5):2551-2561
pubmed: 35852046
FASEB J. 2003 Aug;17(11):1517-9
pubmed: 12824280
Crit Care. 2016 Aug 10;20(1):254
pubmed: 27510990
Science. 2001 Nov 23;294(5547):1704-8
pubmed: 11679633
Clin Rheumatol. 2018 May;37(5):1395-1399
pubmed: 28914380
Clin Res Cardiol. 2020 Jun;109(6):655-672
pubmed: 31562542
FASEB J. 2005 Oct;19(12):1719-21
pubmed: 16051685
Eur Heart J. 2007 Apr;28(7):821-8
pubmed: 17353227